Two unrelated molecules with one shared reputation
BPC-157 and TB-500 are stocked together, sold together and, in the Wolverine stack, injected together. That makes it easy to assume they are two versions of the same idea. They are not.
BPC-157 is a synthetic 15 amino acid sequence built around a fragment of a protective protein found in human gastric juice. Its research history runs through a single Croatian programme that started with stomach ulcers and only later moved to tendons, ligaments and muscle.
TB-500 is the research-market name for a 7 amino acid piece of thymosin beta-4, a 43 amino acid protein found in almost every human cell, where it binds actin and takes part in cell movement. Most of what is published about thymosin beta-4 used the full protein. The short fragment has a much thinner literature of its own.
So a comparison has to start by asking which evidence base actually belongs to which product.
What each evidence base is made of
| BPC-157 | TB-500 (fragment) | |
|---|---|---|
| Built from | Gastric juice protein fragment | Actin-binding region of thymosin beta-4 |
| Length | 15 amino acids | 7 amino acids |
| Bulk of the research | Rat and mouse injury models, mostly one Zagreb group | Full-length thymosin beta-4 studies; fragment-specific data is scarce |
| Human data | One retrospective 16-patient knee-injection survey, no control group | None specific to the fragment; the full protein has eye, wound and cardiac trials |
| Direct head-to-head | One 2026 rat tendon study (both peptides, plus a combination arm) | Same study |
| US FDA compounding status | Nominated to the safety-risk list 2023, withdrawn April 2026 | Nominated 2023 as thymosin beta-4 fragment, withdrawn April 2026 |
| WADA | Not named | Thymosin beta-4 is prohibited at all times |
The first column is deep but narrow: a lot of rodent work, very little of it from outside the originating group, and a 2025 narrative review that concluded the human efficacy and safety picture remains largely unknown. The second column is the opposite problem: a real human trial record exists for thymosin beta-4, but it was earned by a different molecule from the one in the vial.
The one study that compared them directly
In 2026 a Turkish orthopaedic group published the first experiment we could find that put both peptides in the same model. Thirty-two male rats had one Achilles tendon cut and repaired, then were split into four groups of eight: untreated control, BPC-157, TB-500, and both together, with daily intraperitoneal injection for four weeks.
At four weeks:
- Biomechanics. Both treated groups pulled a higher maximum load before the tendon failed than controls. Only the TB-500 group's advantage reached statistical significance.
- Tissue structure. TB-500 produced significantly lower Bonar and Movin scores, the standard histology scales where lower means healthier tendon architecture. The combination group also reached significance on the Movin score. BPC-157's scores were numerically better than control without reaching significance on the totals.
- Collagen. Both treatments shifted type III collagen distribution and the TB-500 group showed the clearest progression toward organised type I collagen.
- Combination. Giving both peptides did not add anything beyond either one alone. The authors' guess is that the two act on overlapping downstream pathways, which they flag as a hypothesis, not a finding.
Read carefully, this is a modest result. Eight rats per group, one time point, one dose per peptide, no dose-ranging, and the authors themselves call it exploratory. It cuts against two popular assumptions at once: that BPC-157 is the stronger tendon healer, and that stacking the two is additive.
What BPC-157's own literature shows
The tendon story for BPC-157 predates that study by 15 years. A 2011 Taiwanese group cut rat Achilles tendons and found BPC-157 improved healing, with cell culture work pointing to more tendon cell outgrowth, better cell survival under stress and more cell migration as the mechanism. Earlier and later papers from Zagreb cover ligament, muscle and bone injury, plus the gut and blood-vessel work that started the programme.
None of this has been tested in a controlled human trial. The single human report, a 2021 chart review from a US hormone clinic, phoned 16 patients six to twelve months after intra-articular BPC-157 injections and asked whether their knee felt better. Most said yes. There was no control group, no blinding, no imaging and no validated outcome scale, which is why the BPC-157 page treats it as documentation that injections happened rather than evidence that they worked.
What TB-500's literature does and does not show
The 2012 review by Goldstein and colleagues, who include the scientists who first characterised thymosin beta-4, lays out the full protein's biology: actin binding, promotion of cell migration, reduced inflammation, and effects in dermal wound, corneal and cardiac injury models, with early human trials in chronic wounds and eye disease.
The catch is the word "full". The fragment sold as TB-500 is built around the LKKTETQ actin-binding sequence on the theory that this piece carries the useful activity. Whether an isolated 7 amino acid fragment behaves like the intact protein in tissue has not been shown, and the FDA's own compounding documents list the fragment as a separate substance with no human exposure data identified. Until the 2026 rat study, there was almost nothing testing the fragment on its own.
Regulatory status
Both were nominated in 2023 to the US FDA's list of bulk substances that may present significant safety risks for compounding, on the same grounds: possible immunogenicity from aggregation and peptide-related impurities, and a lack of human safety data. Both nominations were withdrawn in April 2026 pending review by the agency's compounding advisory committee, which is a procedural step and not an approval.
Neither is registered with FDA Philippines as a medicine, and neither is a controlled substance under RA 9165. Both circulate here as research compounds, usually side by side.
For athletes the two diverge. Thymosin beta-4 is named on the WADA Prohibited List, and the TB-500 fragment falls under that prohibition. BPC-157 is not named, though anti-doping rules also cover non-approved substances as a class.
What this comparison cannot answer
Three things people want from a BPC-157 vs TB-500 page are not in the literature:
- Which one to choose for a given injury. No human trial has tested either for any injury, so there is no basis for matching a peptide to a tendon, ligament or joint.
- Whether a person responds the way a rat does. Rodent tendon healing runs on a faster timeline and a different scale from a human Achilles or rotator cuff, and the 2026 authors say plainly that dose optimisation and longer studies are still needed.
- What a combined vial does. The only combination data is the rat arm above, which found no added benefit.
Both compounds are on this site with an animal-only evidence badge for that reason. The injury healing and joint pain pages rank them against the alternatives, and the side effects hub collects what little adverse-event information exists for each.
Storage
Both are lyophilised powders that keep best refrigerated and away from light, and both go to 2 to 8°C after reconstitution with bacteriostatic water. During a brownout, a cooler with ice packs beats a warming fridge. The BPC-157 calculator and TB-500 calculator handle the reconstitution arithmetic for each.
